Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema
Ophthalmology Retina · 2025-07 · 9 (7) · 655-666
DOI: 10.1016/j.oret.2025.01.017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2025-07. Verfasst von Jennifer I Lim und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois at Chicago, Chicago, Illinois. Electronic address: jennylim@uic.edu. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Macular Edema, Diabetic Retinopathy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS, NEI, F. Hoffmann-La Roche.
Abstract (Originalsprache)
PURPOSE: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME). DESIGN: YOSEMITE/RHINE (NCT03622580/NCT03622593) were identical, randomized, double-masked, active comparator-controlled, 100-week phase III noninferiority trials. PARTICIPANTS: Adults with visual acuity loss due to center-involving DME. METHODS: Patients were randomized 1:1:1 to faricimab 6.0 mg every 8 weeks (Q8W), faricimab 6.0 mg treat-and-extend (T&E), or aflibercept 2.0 mg Q8W for 100 weeks. The T&E up to every 16 weeks dosing regimen was based on central subfield thickness (CST) and best-corrected visual acuity changes. MAIN OUTCOME MEASURES: Post hoc analyses comparing faricimab with aflibercept on CST change; the proportion of eyes with an absence of intraretinal fluid (IRF), subretinal fluid, or both IRF and subretinal fluid or achieving a CST
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Illinois at Chicago, Chicago, Illinois. Electronic address: jennylim@uic.edu.
- Genentech, Inc., South San Francisco, California.
- California Retina Consultants, Santa Barbara, California.
- Vanderbilt Eye Institute, Nashville, Tennessee.
- The University of Sydney, Sydney, Australia; Sydney Eye Hospital, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia.
- Roche Products Ltd., Welwyn Garden City, United Kingdom.
Förderung
- NEI NIH HHS
- NEI
- F. Hoffmann-La Roche
- Research to Prevent Blindness
Zitieren
APA
Lim, J. I., Amador, M. J., Dhoot, D. S., Finn, A., Fraser-Bell, S., Gibson, K., Idowu, O. O., Khurana, R. N., Lanzetta, P., Lin, T. C., Mar, F. A., Pollreisz, A., Rachitskaya, A., Schlottmann, P. G., Tang, Y., & Lai, T. Y. Y. (2025). Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmology Retina, 9(7), 655-666. https://doi.org/10.1016/j.oret.2025.01.017
Vancouver
Lim JI, Amador MJ, Dhoot DS, Finn A, Fraser-Bell S, Gibson K, et al. Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. Ophthalmology Retina. 2025;9(7):655-666. doi:10.1016/j.oret.2025.01.017
BibTeX
@article{Lim2025,
author = {Lim, Jennifer I and Amador, Manuel J and Dhoot, Dilsher S and Finn, Avni and Fraser-Bell, Samantha and Gibson, Kara and Idowu, Oluwatobi O and Khurana, Rahul N and Lanzetta, Paolo and Lin, Tai-Chi and Mar, Florie A and Pollreisz, Andreas and Rachitskaya, Aleksandra and Schlottmann, Patricio G and Tang, Yannan and Lai, Timothy Y Y},
title = {Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema},
journal = {Ophthalmology Retina},
year = {2025},
volume = {9},
number = {7},
pages = {655--666},
doi = {10.1016/j.oret.2025.01.017}
}
EUVIMED